|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM32A |
Gene summary for FAM32A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM32A | Gene ID | 26017 |
| Gene name | family with sequence similarity 32 member A | |
| Gene Alias | OTAG-12 | |
| Cytomap | 19p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A024R7I4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26017 | FAM32A | HTA11_10623_2000001011 | Human | Colorectum | AD | 2.86e-10 | 4.47e-01 | -0.0177 |
| 26017 | FAM32A | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.53e-03 | 3.76e-01 | 0.0171 |
| 26017 | FAM32A | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.34e-04 | 2.28e-01 | 0.0338 |
| 26017 | FAM32A | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.22e-11 | 3.99e-01 | 0.0674 |
| 26017 | FAM32A | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.11e-04 | 2.72e-01 | 0.0588 |
| 26017 | FAM32A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.82e-13 | 3.68e-01 | 0.294 |
| 26017 | FAM32A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 8.00e-08 | 8.87e-01 | 0.3487 |
| 26017 | FAM32A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.46e-11 | 3.89e-01 | 0.281 |
| 26017 | FAM32A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.23e-19 | 4.72e-01 | 0.3859 |
| 26017 | FAM32A | HTA11_99999973899_84307 | Human | Colorectum | MSS | 6.29e-15 | 6.10e-01 | 0.2585 |
| 26017 | FAM32A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.14e-09 | 3.04e-01 | 0.3005 |
| 26017 | FAM32A | LZE2D | Human | Esophagus | HGIN | 1.55e-02 | 9.06e-02 | 0.0642 |
| 26017 | FAM32A | LZE2T | Human | Esophagus | ESCC | 2.19e-05 | 2.83e-01 | 0.082 |
| 26017 | FAM32A | LZE3D | Human | Esophagus | HGIN | 2.35e-02 | 2.54e-01 | 0.0668 |
| 26017 | FAM32A | LZE4T | Human | Esophagus | ESCC | 1.19e-14 | 3.91e-01 | 0.0811 |
| 26017 | FAM32A | LZE5T | Human | Esophagus | ESCC | 2.22e-02 | 1.84e-01 | 0.0514 |
| 26017 | FAM32A | LZE7T | Human | Esophagus | ESCC | 2.34e-11 | 8.40e-01 | 0.0667 |
| 26017 | FAM32A | LZE8T | Human | Esophagus | ESCC | 1.52e-15 | 1.45e-01 | 0.067 |
| 26017 | FAM32A | LZE20T | Human | Esophagus | ESCC | 3.27e-06 | 1.96e-01 | 0.0662 |
| 26017 | FAM32A | LZE22D1 | Human | Esophagus | HGIN | 1.55e-06 | 1.12e-01 | 0.0595 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM32A | SNV | Missense_Mutation | c.196N>C | p.Glu66Gln | p.E66Q | Q9Y421 | protein_coding | tolerated(0.32) | probably_damaging(0.987) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM32A | SNV | Missense_Mutation | novel | c.271N>A | p.Asp91Asn | p.D91N | Q9Y421 | protein_coding | tolerated(0.09) | benign(0.041) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM32A | SNV | Missense_Mutation | c.182N>T | p.Ala61Val | p.A61V | Q9Y421 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FAM32A | SNV | Missense_Mutation | novel | c.38A>C | p.Lys13Thr | p.K13T | Q9Y421 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| FAM32A | SNV | Missense_Mutation | c.138G>T | p.Lys46Asn | p.K46N | Q9Y421 | protein_coding | tolerated(0.27) | probably_damaging(0.911) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FAM32A | SNV | Missense_Mutation | novel | c.121N>G | p.Met41Val | p.M41V | Q9Y421 | protein_coding | tolerated(0.48) | benign(0.028) | TCGA-WX-AA44-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PR |
| FAM32A | SNV | Missense_Mutation | c.332C>T | p.Thr111Met | p.T111M | Q9Y421 | protein_coding | deleterious(0.02) | benign(0.09) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM32A | SNV | Missense_Mutation | novel | c.305N>G | p.His102Arg | p.H102R | Q9Y421 | protein_coding | deleterious(0) | benign(0.029) | TCGA-VQ-A8E3-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |